BioCentury
ARTICLE | Product Development

Mimicking viral infections

November 2, 2009 8:00 AM UTC

Marketed vaccine adjuvants are effective at increasing the antibody response to the vaccine antigen, but few non-replicating adjuvants generate strong T cell responses, which limits their effectiveness in the elderly and against many infectious agents.

Juvaris BioTherapeutics Inc. hopes the ability of its JVRS-100 adjuvant to generate both antibody and T cell responses will translate into better protection in populations not served by existing vaccines, as well as dose conservation for vaccines with limited supply. On Monday this week, the company was to announce the start of a Phase II trial of JVRS-100 in combination with Fluzone influenza vaccine from sanofi-aventis Group...